Anti-TNFR2 Antibody-Conjugated PLGA Nanoparticles for Targeted Delivery of Adriamycin in Mouse Colon Cancer.

ABSTRACT: High levels of tumor necrosis factor receptor type II (TNFR2) are preferentially expressed by immunosuppressive CD4⁺Foxp3⁺ regulatory T cells (T_regs), especially those present in the tumor microenvironment, as initially reported by us. There is compelling evidence that targeting TNFR2 markedly enhances antitumor immune responses. Furthermore, a broad spectrum of human cancers also expresses TNFR2, while its expression by normal tissue is very limited. We thus hypothesized that TNFR2 may be harnessed for tumor-targeted delivery of chemotherapeutic agents. In this study, we performed a proof-of-concept study by constructing a TNFR2-targeted PEGylated poly(dl-lactic-co-glycolic acid) (PLGA-PEG) nanodrug delivery system [designated as TNFR2-PLGA-ADR (Adriamycin

SUBMITTER: Li P 

PROVIDER: S-EPMC11377996 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature